Back to All Stocks

Gilead Sciences Inc. (GILD) Stock Forecast

AI-powered analysis with bull/bear cases, price targets, and news sentiment

Gilead Sciences Inc. (GILD) is a US-listed company in the Biotechnology sector. The analysis below explains how investors typically evaluate a business of this type, the valuation assumptions our model applies to the sector, and how Gilead Sciences Inc. compares with its peers.

Sector: Biotechnology · AI-assisted analysis, refreshed periodically. Not financial advice. See our disclaimer.

Gilead Sciences Inc. at a glance

Gilead Sciences Inc. trades under the ticker GILD on the NASDAQ and is classified in the Biotechnology sector. This page brings together a live AI forecast, a discounted-cash-flow (DCF) valuation, and the fundamentals investors most often look at before taking a position.

Because Gilead Sciences Inc. sits in the Biotechnology space, its results tend to move with the drivers specific to that sector. The valuation framework below reflects the growth, risk and discount-rate assumptions we apply to Biotechnology companies rather than a one-size-fits-all model.

How we value a Biotechnology stock like Gilead Sciences Inc.

Our 3-stage DCF model projects earnings for Gilead Sciences Inc. using sector-calibrated growth: roughly 14.0% EPS growth in the high-growth phase (years 1–5), fading to about 9.0% (years 6–10), and a long-run terminal growth of 3.5%.

Those cash flows are discounted at an estimated cost of equity of 10.6%, built from a 4.5% risk-free rate, a sector beta of 1.10, and an equity risk premium of 5.5% (CAPM). The output is an intrinsic value per share and a "margin of safety" versus the current $ market price — shown live in the Valuation tab.

A near-market beta means Gilead Sciences Inc. has roughly tracked the broader index in volatility terms.

Key things to watch with Gilead Sciences Inc.

Before relying on any single number, sanity-check the inputs: is the current P/E reasonable versus Gilead Sciences Inc.'s own history and its Biotechnology peers? Are earnings growing on a durable basis, or boosted by one-offs? How sensitive is the intrinsic value if growth comes in a couple of points below the sector assumption?

The AI Forecast tab adds qualitative colour — bull and bear cases, catalysts and risks — while the Valuation tab keeps the maths transparent. Treat both as a research starting point, not a recommendation.

Frequently asked questions about GILD

What sector does Gilead Sciences Inc. (GILD) belong to?

Gilead Sciences Inc. is classified in the Biotechnology sector, alongside peers such as Amgen Inc., Regeneron Pharmaceuticals, Moderna Inc.. Sector classification drives the growth and risk assumptions used in its DCF valuation.

How is Gilead Sciences Inc.'s intrinsic value calculated?

We run a 3-stage discounted-cash-flow model using Biotechnology-calibrated EPS growth (high-growth ~14.0%, fade ~9.0%, terminal 3.5%) discounted at an estimated cost of equity of 10.6%. The result is compared against the live $ price to give a margin of safety.

Is Gilead Sciences Inc. a good long-term investment?

That depends on your goals, risk tolerance and the price you pay. This page gives you the tools — intrinsic value, margin of safety, P/E context and an AI bull/bear view — to make that judgement, but it is educational analysis and not financial advice. Always do your own research or consult a licensed adviser.

How often is the Gilead Sciences Inc. analysis updated?

The live price and fundamentals refresh on each visit where data is available, while the AI commentary is regenerated periodically. The valuation recomputes from the latest price, so the margin of safety always reflects current market conditions.